Yuh Shan Lee

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Mohammed Farooqui, Janet Valdez, Sabrina Martyr et al. · The Lancet Oncology · 2014 · 366 citations · Full text

Medicine, Immunology, Oncology +11

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib

Clare Sun, Xin Tian, Yuh Shan Lee et al. · Blood · 2015 · 221 citations · Full text

Life Sciences, Hematology, Immunology +14

Disruption of <i>in vivo</i> Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study

Carsten Utoft Niemann, Sarah E. M. Herman, Irina Marić et al. · Clinical Cancer Research · 2015 · 194 citations · Full text

Medicine, Immunology, Oncology +17

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy

Martin Skarzynski, Carsten Utoft Niemann, Yuh Shan Lee et al. · Clinical Cancer Research · 2015 · 80 citations · Full text

Pharmacy, Immunology, Pharmacology +16

Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial

Daryl Tan, Colin Phipps, William Ying Khee Hwang et al. · The Lancet Haematology · 2015 · 62 citations

Medicine, Hematology, Oncology +14